BR112022024745A2 - Melhora de tolerabilidade de anticorpo associada a administração intravenosa - Google Patents

Melhora de tolerabilidade de anticorpo associada a administração intravenosa

Info

Publication number
BR112022024745A2
BR112022024745A2 BR112022024745A BR112022024745A BR112022024745A2 BR 112022024745 A2 BR112022024745 A2 BR 112022024745A2 BR 112022024745 A BR112022024745 A BR 112022024745A BR 112022024745 A BR112022024745 A BR 112022024745A BR 112022024745 A2 BR112022024745 A2 BR 112022024745A2
Authority
BR
Brazil
Prior art keywords
antibody
administration
administering
intravenous
mice
Prior art date
Application number
BR112022024745A
Other languages
English (en)
Portuguese (pt)
Inventor
Frendéus Björn
Mårtensson Linda
Teige Ingrid
KARLSSON Ingrid
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20178287.7A external-priority patent/EP3919077A1/en
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Publication of BR112022024745A2 publication Critical patent/BR112022024745A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR112022024745A 2020-06-04 2021-06-04 Melhora de tolerabilidade de anticorpo associada a administração intravenosa BR112022024745A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20178287.7A EP3919077A1 (en) 2020-06-04 2020-06-04 Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
EP21163703 2021-03-19
PCT/EP2021/065014 WO2021245238A1 (en) 2020-06-04 2021-06-04 Improving antibody tolerability associated with intravenous administration

Publications (1)

Publication Number Publication Date
BR112022024745A2 true BR112022024745A2 (pt) 2023-03-07

Family

ID=76217874

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024745A BR112022024745A2 (pt) 2020-06-04 2021-06-04 Melhora de tolerabilidade de anticorpo associada a administração intravenosa

Country Status (12)

Country Link
US (2) US20230322933A1 (https=)
EP (2) EP4161574A1 (https=)
JP (1) JP2023527926A (https=)
KR (1) KR20230038180A (https=)
CN (1) CN116322767A (https=)
AU (1) AU2021286202A1 (https=)
BR (1) BR112022024745A2 (https=)
CA (1) CA3185020A1 (https=)
IL (1) IL298757A (https=)
MX (1) MX2022015229A (https=)
TW (3) TW202210103A (https=)
WO (3) WO2021245238A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342057A (zh) * 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2196002T3 (es) 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
EP2490715A4 (en) * 2009-10-21 2013-06-26 Immunogen Inc NEW DOSAGE ADMINISTRATION REGIMEN AND METHOD OF TREATMENT
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
AU2016378573A1 (en) * 2015-12-22 2018-07-19 Regeneron Pharmaceuticals, Inc. Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia
WO2019081983A1 (en) * 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
EP3737698A2 (en) 2018-01-10 2020-11-18 BioInvent International AB Novel combination and use of antibodies
MX2021001058A (es) 2018-08-16 2021-04-12 Genmab As Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de un cancer.
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies

Also Published As

Publication number Publication date
TW202210103A (zh) 2022-03-16
CA3185020A1 (en) 2021-12-09
JP2023527926A (ja) 2023-06-30
WO2021245237A1 (en) 2021-12-09
US20240301070A1 (en) 2024-09-12
AU2021286202A1 (en) 2023-01-19
US20230322933A1 (en) 2023-10-12
WO2021245238A1 (en) 2021-12-09
EP4161574A1 (en) 2023-04-12
TW202210102A (zh) 2022-03-16
WO2021245238A9 (en) 2023-02-02
KR20230038180A (ko) 2023-03-17
IL298757A (en) 2023-02-01
TW202210104A (zh) 2022-03-16
EP4161573A1 (en) 2023-04-12
CN116322767A (zh) 2023-06-23
WO2021245233A1 (en) 2021-12-09
MX2022015229A (es) 2023-02-09

Similar Documents

Publication Publication Date Title
Alvarez et al. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
Pradhan et al. d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R, S)-ketamine infusion and TIMBER psychotherapy: a pilot study
Henter et al. Glutamatergic modulators in depression
Mahableshwarkar et al. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder
Samara et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis
Rothschild et al. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States
Glanz et al. Inhibition of sialidase activity as a therapeutic approach
Italiano et al. Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants
Hellerstein et al. Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy
Carvalho et al. N-acetylcysteine augmentation to tranylcypromine in treatment-resistant major depression
Woo et al. Lurasidone as a potential therapy for bipolar disorder
BR112022024745A2 (pt) Melhora de tolerabilidade de anticorpo associada a administração intravenosa
BR112021023354A2 (pt) Métodos e composições farmacêuticas para tratar sobredose de fármaco
Gómez-Outes et al. Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients
Yapa et al. Critical review: what dose of rifabutin is recommended with antiretroviral therapy?
Sheehan et al. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study
Mann et al. Rethinking the medication management of major depression
Maulidiyah et al. Successful resolution of mesenteric tuberculosis and HIV co-infection following 6 months of anti-tuberculosis therapy: A case report
Evans et al. Psychedelic therapy: a primer for primary care clinicians—ketamine
Carpiniello et al. Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
Di Pierro et al. Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression
Lourenco et al. Desvenlafaxine in the treatment of major depressive disorder
Lin et al. Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo
Vitrone et al. Drugs and liver injury: a not to be overlooked binomial in COVID-19
McCance-Katz Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women